Nortriptyline HCl
A to Z Drug Facts
Nortriptyline HCl |
(nor-TRIP-tih-leen HIGH-droe-KLOR-ide) |
Aventyl HCl, Aventyl HCl Pulvules, Pamelor, ![]() |
Class: Tricyclic antidepressant |
Action Inhibits reuptake of norepinephrine and serotonin in CNS.
Indications Relief of symptoms of depression. unlabeled use(s): Treatment of panic disorder, premenstrual depression, dermatologic disorders (eg, chronic urticaria, angioedema, nocturnal pruritis in atopic eczema).
Contraindications Hypersensitivity to any tricyclic antidepressant. Generally, not to be given in combination with or within 14 days of treatment with MAO inhibitors or during acute recovery phases of MI.
ADULTS: PO 25 mg tid to qid. Doses > 150 mg/day are not recommended. ELDERLY & ADOLESCENTS: PO 30 to 50 mg/day in divided doses.
Anticoagulants: Dicumaral actions may increase. Carbamazepine: Carbamazepine levels may increase; nortriptyline levels may decrease. Cimetidine, fluoxetine: Concomitant administration may increase nortriptyline blood levels and effects. CNS depressants: Depressant effects may be additive. Clonidine: May result in hypertensive crisis. Guanethidine: Hypotensive action may be inhibited. MAO Inhibitors: Hyperpyretic crisis, convulsions and death may occur. Sympathomimetics: Pressor response may decrease.
Lab Test Interferences None well documented.
CV: Orthostatic hypotension; hypertension; tachycardia; palpitations; arrhythmias; ECG changes; stroke; heart block; CHF. RESP: Pharyngitis; rhinitis; sinusitis; laryngitis; coughing. CNS: Confusion; hallucinations; delusions; nervousness; restlessness; agitation; panic; insomnia; nightmares; mania; exacerbation of psychosis; drowsiness; dizziness; weakness; fatigue; emotional lability; seizures; tremors; extrapyramidal symptoms (eg, pseudoparkinsonism, movement disorders, akathisia). EENT: Nasal congestion; tinnitus; conjunctivitis; mydriasis; blurred vision; increased IOP; peculiar taste in mouth. GI: Nausea; vomiting; anorexia; GI distress; diarrhea; flatulence; dry mouth; constipation. GU: Impotence; sexual dysfunction; nocturia; urinary frequency; urinary tract infection; vaginitis; cystitis; dysmenorrhea; amenorrhea; urinary retention and hesitancy. HEMA: Bone marrow depression including agranulocytosis; eosinophilia; purpura; thrombocytopenia; leukopenia. DERM: Rash; pruritus; photosensitivity reaction; dry skin; acne. HEPA: Hepatitis; jaundice. META: Elevation or depression of blood sugar. OTHER: Numbness; breast enlargement.
Pregnancy: Category D. Safety not established. Limb reduction anomalies have been reported with nortriptyline. Lactation: Excreted in breast milk. Children: Safety and efficacy not established. Special-risk patients: Use drug with caution in patients with history of seizures, urinary retention, urethral or ureteral spasm, angle-closure glaucoma or increased IOP, cardiovascular disorders, hyperthyroid patients or those receiving thyroid medication, patients with hepatic or renal impairment, schizophrenia or paranoia.
PATIENT CARE CONSIDERATIONS |
|
|
Books@Ovid
Copyright © 2003 Facts and Comparisons
David S. Tatro
A to Z Drug Facts